Chronic Kidney Disease Drugs Market size and Key Trends in terms of volume and value 2016-2024

Global Chronic Kidney Disease Drugs Market: Snapshot

The global market for chronic kidney disease drugs continues to proliferate at a significant pace, driven by the increasing number of chronic kidney disease patients and the growing need of novel treatments to improve patients’ quality of life. The increasing number of elderly people, who are more vulnerable to various diseases due to poor immunity, such as cardiovascular disorders, diabetes, and neurological conditions, is another important factor behind the growth of this market, as, owing to this, the prevalence of these diseases is rising considerably across the world.

This 143 page report gives readers a comprehensive overview of the chronic kidney disease drugs market. Browse through 19 data tables and 58 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/chronic-kidney-disease.html

Going forward, the market is projected to be propelled substantially in the near future by the technological advancements, leading to the development of a wide array of drugs, which will enable clinicians to provide proper assistance to chronic kidney disease patients. The global chronic kidney disease drugs market stood at US$11.5 bn in 2015. Burgeoning at a CAGR of 3.60% between 2016 and 2024, the market’s opportunity is expected to reach US$15.8 bn by the end of 2024.

Calcium Channel Blockers to Remain Market Leader Supported by Strong Demand

The global market for chronic kidney disease drugs is studied on the basis of a number of parameters, among which the drug class is a prominent one. Based on the drug class, the market is classified primarily into ACE Inhibitors, Angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), and diuretics.

Calcium channel blockers surfaced as the key drug class in 2015, leading the market with a share of 18.9%. Currently, the main calcium channel blockers utilized across the world are benzothiazepines (diltiazem), phenyl alkyl amines (verapamil), and dihydropiridines (nifedipine and amlodipine).

Hospitals and specialty clinics are the prime end users of chronic kidney disease drugs. The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years.

Strong Economic Conditions to Prove Favorable for North America Chronic Kidney Disease Drugs Market

The worldwide chronic kidney disease drugs market is stretched across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America led this market in 2015 with a share of 31.8%. Driven by the strong economic condition of the region and the high acceptance for advanced technology products, the North America chronic kidney disease drugs market is likely to maintain its lead over the forthcoming years. The increasing cases of diabetes and obesity related disorders are also projected to boost this regional market in the near future.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving chronic kidney disease drugs market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2481

Europe, which was the second leading market for chronic kidney disease drugs across the world in 2015, is likely to present the most attractive growth opportunities to market players in the years to come due to the increasing pool of kidney cancer patients in this region. The high rate of adoption and usage of superior quality treatments for these diseases is also predicted to aid the Europe chronic kidney disease drugs market over the next few years. The significant expansion of the medical and healthcare industry in China, Japan, and Australia is likely to drive the Asia Pacific market for chronic kidney disease drugs in the near future.

Teva Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca Plc, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, AbbVie Inc., Kissei Pharmaceutical Co. Ltd., and Keryx Biopharmaceuticals Inc. are some of the leading makers of drugs for the treatment of chronic kidney diseases across the world.

Chronic Kidney Disease Drugs Market size and Key Trends in terms of volume and value 2016-2024

The global chronic kidney disease drugs market is largely fragmented, states a research report by Transparency Market Research (TMR). The top four players, namely Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for a share of only 41.4% in this market in 2015.

The prominent players in this market are focusing aggressively on mergers, acquisitions, and strategic alliances to expand their product portfolio, which is likely to lead to market consolidation in the next few years, reports the research study.

According to the report’s estimations, the global market for chronic kidney disease drugs was worth US$11.5 bn in 2015. Proliferating at a 3.60% CAGR during the period from 2016 to 2024, the overall opportunity in this market is anticipated to increase to US$15.8 bn by the end of the forecast period. Hospitals have surfaced as the key end users of chronic kidney disease drugs and are projected to remain so over the next few years.

This 143 page report gives readers a comprehensive overview of the chronic kidney disease drugs market. Browse through 19 data tables and 58 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/chronic-kidney-disease.html

North America Chronic Kidney Disease Drug Market to Report Greater Rise than Other Regional Markets

The report states that the worldwide market for chronic kidney disease drugs is spread across Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. In 2015, North America dominated this market with a share of 31.8%. Researchers predict this regional market to retain its position over the forecast period, thanks to the high adoption rate of advanced technology products and the presence of a state-of-art medical and healthcare industry. The rising prevalence of diabetes and the alarming growth in the obese population are also expected to drive this regional market in the years to come.

On the other hand, Europe, which stood second in 2015, is likely to offer the most promising growth opportunities to market players over the next few years on the grounds of the rising pool of patients suffering from kidney cancer in Europe. The growing uptake of high quality and expensive treatments for these diseases in this region are also projected to boost the market for kidney disease drugs in Europe in the near future, states the market study.

Advancements in Chronic Kidney Disease Drugs to Propel Market

“The significant rise in the pool of patients suffering from chronic kidney diseases and the growing demand for new and advanced treatments to increase their longevity are having a major impact on the demand for chronic kidney disease drugs across the world,” says a researcher at TMR. Another important factor boosting this market is the rising number of elderly people, prone to a variety of diseases, such as diabetes cardiovascular disorders, and several neurological conditions, thanks to their poor immunity. As these diseases affect the kidney severely, the chances of elderly people to contract chronic kidney diseases are much higher, which eventually, reflects on the demand for chronic kidney disease drugs.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving chronic kidney disease drugs market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2481

Over the coming years, the innovations and technological advancements in these drugs, enabling clinicians to offer proper assistance to the patients, are likely to boost this market remarkably. However, the increasing preference for generic drug variants among consumers and the intensifying competition from biosimilars due to patent loss may restrict the growth of this market in the near future, notes the research study.

The study presented here is based on a report by Transparency Market Research (TMR), titled “Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-stimulating Agents (ESAs), and Diuretics; End User - Hospitals and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Chronic Kidney Disease Drugs Market size and Key Trends in terms of volume and value 2016-2024

Global Chronic Kidney Disease Drugs Market: Snapshot

The global market for chronic kidney disease drugs continues to proliferate at a significant pace, driven by the increasing number of chronic kidney disease patients and the growing need of novel treatments to improve patients’ quality of life. The increasing number of elderly people, who are more vulnerable to various diseases due to poor immunity, such as cardiovascular disorders, diabetes, and neurological conditions, is another important factor behind the growth of this market, as, owing to this, the prevalence of these diseases is rising considerably across the world.

Going forward, the market is projected to be propelled substantially in the near future by the technological advancements, leading to the development of a wide array of drugs, which will enable clinicians to provide proper assistance to chronic kidney disease patients. The global chronic kidney disease drugs market stood at US$11.5 bn in 2015. Burgeoning at a CAGR of 3.60% between 2016 and 2024, the market’s opportunity is expected to reach US$15.8 bn by the end of 2024.

Obtain Report Details: http://www.transparencymarketresearch.com/chronic-kidney-disease.html

Calcium Channel Blockers to Remain Market Leader Supported by Strong Demand

The global market for chronic kidney disease drugs is studied on the basis of a number of parameters, among which the drug class is a prominent one. Based on the drug class, the market is classified primarily into ACE Inhibitors, Angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), and diuretics.

Calcium channel blockers surfaced as the key drug class in 2015, leading the market with a share of 18.9%. Currently, the main calcium channel blockers utilized across the world are benzothiazepines (diltiazem), phenyl alkyl amines (verapamil), and dihydropiridines (nifedipine and amlodipine).

Hospitals and specialty clinics are the prime end users of chronic kidney disease drugs. The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years.

Strong Economic Conditions to Prove Favorable for North America Chronic Kidney Disease Drugs Market

The worldwide chronic kidney disease drugs market is stretched across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America led this market in 2015 with a share of 31.8%. Driven by the strong economic condition of the region and the high acceptance for advanced technology products, the North America chronic kidney disease drugs market is likely to maintain its lead over the forthcoming years. The increasing cases of diabetes and obesity related disorders are also projected to boost this regional market in the near future.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2481

Europe, which was the second leading market for chronic kidney disease drugs across the world in 2015, is likely to present the most attractive growth opportunities to market players in the years to come due to the increasing pool of kidney cancer patients in this region. The high rate of adoption and usage of superior quality treatments for these diseases is also predicted to aid the Europe chronic kidney disease drugs market over the next few years. The significant expansion of the medical and healthcare industry in China, Japan, and Australia is likely to drive the Asia Pacific market for chronic kidney disease drugs in the near future.

Teva Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca Plc, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, AbbVie Inc., Kissei Pharmaceutical Co. Ltd., and Keryx Biopharmaceuticals Inc. are some of the leading makers of drugs for the treatment of chronic kidney diseases across the world.